Immunogenicity, Reactogenicity and Safety of the Trivalent Influenza Subunit Vaccine Influvac for the Northern Hemisphere Season 2012/2013. An Open-Label, Baseline- Controlled Study in Two Age Groups: Adult Subjects ≥ 18 and ≤ 60 Years and Elderly Subjects ≥ 61 Years of Age

Trial Profile

Immunogenicity, Reactogenicity and Safety of the Trivalent Influenza Subunit Vaccine Influvac for the Northern Hemisphere Season 2012/2013. An Open-Label, Baseline- Controlled Study in Two Age Groups: Adult Subjects ≥ 18 and ≤ 60 Years and Elderly Subjects ≥ 61 Years of Age

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Aug 2014

At a glance

  • Drugs Influenza virus vaccine (Primary)
  • Indications Influenza virus infections
  • Focus Adverse reactions; Pharmacodynamics; Registrational; Therapeutic Use
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 03 Aug 2012 Actual end date (Jul 2012) added as reported by ClinicalTrials.gov.
    • 13 Jul 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 13 Jul 2012 Additional location [Germany] and lead trial investigator identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top